NanoPhoria

NanoPhoriaNanoPhoria
N

NanoPhoria

Developing inhalable therapies for cardiovascular diseases using a proprietary nanoparticle platform.

ActiveItaly
Rate
Advertise here

About

NanoPhoria is a preclinical-stage biotechnology company focused on developing novel inhalable therapies for cardiovascular diseases. Their core technology utilizes a proprietary, non-viral calcium phosphate nanoparticle platform designed to deliver biologics, such as peptides and RNA, directly to target tissues. This approach aims to enhance treatment effectiveness and minimize systemic side effects by enabling precise, tissue-directed drug delivery via inhalation, with an initial focus on conditions like heart failure.
Frequently asked

What does NanoPhoria do?

NanoPhoria is a preclinical-stage biotechnology company focused on developing novel inhalable therapies for cardiovascular diseases. Their core technology utilizes a proprietary, non-viral calcium phosphate nanoparticle platform designed to deliver biologics, such as peptides and RNA, directly to target tissues. This approach aims to enhance treatment effectiveness and minimize systemic side effects by enabling precise, tissue-directed drug delivery via inhalation, with an initial focus on condi…

What is NanoPhoria's revenue?

StartupHub estimates NanoPhoria's annual revenue at $6.7M (range $2.7M to $30.6M, 34% confidence), based on comparable companies in the sector.

What is NanoPhoria's valuation?

StartupHub estimates NanoPhoria's effective valuation at $288.9M (range $208.8M to $501.0M, 18% confidence), based on comparable companies in the sector.

How much funding has NanoPhoria raised?

NanoPhoria has raised a total of $84M in funding. The most recent round on record is null.

Where is NanoPhoria headquartered?

NanoPhoria is headquartered in Italy.

What industry does NanoPhoria operate in?

NanoPhoria operates in Biotechnology, Healthcare, Pharmaceuticals, Medical Devices.

Comments

No comments yet. Be the first to share your take.